DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Aclarubicin is an investigational drug.
There have been 8 clinical trials for Aclarubicin. The most recent clinical trial was a Phase 1 trial, which was initiated on March 24th 2021.
The most common disease conditions in clinical trials are Leukemia, Myeloid, Leukemia, and Leukemia, Myeloid, Acute. The leading clinical trial sponsors are Sun Yat-sen University, Jingjiang People's Hospital, and Second Affiliated Hospital of Soochow University.
There are six hundred and forty-one US patents protecting this investigational drug and nine international patents.
Recent Clinical Trials for Aclarubicin
|A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated||CSPC ZhongQi Pharmaceutical Technology Co., Ltd.||Phase 3|
|Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML||Sun Yat-sen University||Phase 2|
|A Phase 2 Study of Venetoclax in Combination With Low-dose HHT, G-CSF, and AZA as First-line Treatment for Newly Diagnosed Elderly AML Patients Unfit for Intensive Chemotherapy||Shanghai Jiao Tong University School of Medicine||Phase 2|
Top disease conditions for Aclarubicin
Top clinical trial sponsors for Aclarubicin
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Aclarubicin||⤷ Try it Free||Heterocyclic compounds useful in the treatment of disease||Epigen Biosciences, Inc. (San Diego, CA)||⤷ Try it Free|
|Aclarubicin||⤷ Try it Free||Heat shock protein 70 (hsp-70) receptor ligands||Duke University (Durham, NC)||⤷ Try it Free|
|Aclarubicin||⤷ Try it Free||Compounds and their methods of use||Agios Pharmaceuticals, Inc. (Cambridge, MA)||⤷ Try it Free|
|Aclarubicin||⤷ Try it Free||Heterocyclic compound||Takeda Pharmaceutical Company Limited (Osaka, JP)||⤷ Try it Free|
|Aclarubicin||⤷ Try it Free||Method of diagnosing and treating cancer using B-catenin splice variants||The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC)||⤷ Try it Free|
|Aclarubicin||⤷ Try it Free||Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers||Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC)||⤷ Try it Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Aclarubicin||Australia||AU2014232383||2033-03-15||⤷ Try it Free|
|Aclarubicin||Australia||AU2019202731||2033-03-15||⤷ Try it Free|
|Aclarubicin||Australia||AU2019288275||2033-03-15||⤷ Try it Free|
|Aclarubicin||Brazil||BR112015023267||2033-03-15||⤷ Try it Free|
|Aclarubicin||Brazil||BR112020025927||2033-03-15||⤷ Try it Free|
|Aclarubicin||Canada||CA2906931||2033-03-15||⤷ Try it Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|